Vaccine design for severe acute respiratory syndrome coronavirus
- PMID: 16035944
- DOI: 10.1089/vim.2005.18.327
Vaccine design for severe acute respiratory syndrome coronavirus
Abstract
Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a new coronavirus (SARS-CoV). Recent studies suggest that SARS-CoV is zoonotic and may have a broad host range besides humans. Although the global outbreak of SARS has been contained, there are serious concerns over its re-emergence and bioterrorism potential. As a part of preparedness, development of a safe and effective vaccine is one of the highest priorities in fighting SARS. A number of candidate vaccines, using a variety of approaches, are under development. The first vaccine tested in clinical trial is made from the inactivated form of SARS-CoV. Several live attenuated, genetically engineered or vector vaccines encoding the SARS-CoV spike (S) protein have been in pre-clinical studies. These vaccine candidates are effective in terms of eliciting protective immunity in the vaccinated animals. However, caution should be taken with the safety of whole virus or full-length S protein-based immunogens in humans because they may induce harmful immune or inflammatory responses. We propose to use the receptor-binding domain (RBD) of SARS-CoV S protein (residues 318--510) for developing a safe and effective subunit SARS vaccine, as it is not only a functional domain that mediates virus-receptor binding but also a major neutralization determinant of SARSCoV. It has been demonstrated that the RBD of SARS-CoV S protein contains multiple conformational epitopes capable of inducing highly potent neutralizing antibody responses and protective immunity.
Similar articles
-
SARS vaccine development.Emerg Infect Dis. 2005 Jul;11(7):1016-20. doi: 10.3201/1107.050219. Emerg Infect Dis. 2005. PMID: 16022774 Free PMC article. Review.
-
Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.Virology. 2005 Mar 30;334(1):74-82. doi: 10.1016/j.virol.2005.01.034. Virology. 2005. PMID: 15749124 Free PMC article.
-
Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.J Virol. 2005 Mar;79(5):2678-88. doi: 10.1128/JVI.79.5.2678-2688.2005. J Virol. 2005. PMID: 15708987 Free PMC article.
-
Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.J Virol. 2004 Jul;78(13):6938-45. doi: 10.1128/JVI.78.13.6938-6945.2004. J Virol. 2004. PMID: 15194770 Free PMC article.
-
Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.Avian Pathol. 2003 Dec;32(6):567-82. doi: 10.1080/03079450310001621198. Avian Pathol. 2003. PMID: 14676007 Free PMC article. Review.
Cited by
-
Factors, enablers and challenges for COVID-19 vaccine development.BMJ Glob Health. 2023 Jun;8(6):e011879. doi: 10.1136/bmjgh-2023-011879. BMJ Glob Health. 2023. PMID: 37277195 Free PMC article. Review.
-
DNA Oligonucleotides as Antivirals and Vaccine Constituents against SARS Coronaviruses: A Prospective Tool for Immune System Tuning.Int J Mol Sci. 2023 Jan 13;24(2):1553. doi: 10.3390/ijms24021553. Int J Mol Sci. 2023. PMID: 36675069 Free PMC article.
-
Respiratory illness virus infections with special emphasis on COVID-19.Eur J Med Res. 2022 Nov 8;27(1):236. doi: 10.1186/s40001-022-00874-x. Eur J Med Res. 2022. PMID: 36348452 Free PMC article. Review.
-
Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic.Osong Public Health Res Perspect. 2022 Apr;13(2):84-100. doi: 10.24171/j.phrp.2022.0024. Epub 2022 Apr 27. Osong Public Health Res Perspect. 2022. PMID: 35538681 Free PMC article.
-
A global survey in the developmental landscape of possible vaccination strategies for COVID-19.Clin Immunol. 2022 Apr;237:108958. doi: 10.1016/j.clim.2022.108958. Epub 2022 Feb 24. Clin Immunol. 2022. PMID: 35218966 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous